SAB BIO Confirms $175M Funding, Advances Registrational Diabetes Drug Study, Secures Runway to 2028
SABS has more than doubled off its 52-week low of $1.
Summary
SAB Biotherapeutics reported full-year 2025 business highlights, including the successful completion of a $175 million oversubscribed private placement in July 2025, which fully funds its registrational Phase 2b SAFEGUARD study for SAB-142 in type 1 diabetes. The company also confirmed positive Phase 1 data and that the Phase 2b study is initiated, enrolling patients, and on track for completion by end of 2026 with topline data in 2H 2027. This is a highly material update for a clinical-stage biotech with a market cap of approximately $182 million, as the substantial financing provides a strong cash position and operational runway through 2028, significantly de-risking the company's financial future and its ability to advance its lead asset. The progress of the registrational Phase 2b study and positive Phase 1 data are critical milestones for the company's pipeline. Investors will monitor enrollment progress for the SAFEGUARD study and anticipate the topline data expected in the second half of 2027.
At the time of this announcement, SABS was trading at $3.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $182.8M. The 52-week trading range was $1.00 to $6.60. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.